Fas and FasL expression on cells of two transplantable melanoma lines according to their different biological properties

Folia Histochemica et Cytobiologica

Volumn 46, Issue 3, 2008, Pages 337-343

  Zielińska, Katarzyna ^a   Kozłowska, Krystyna ^a   Cichorek, Mirosława ^a   Wachulska, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Fas; FasL; Transplantable melanoma

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

AMELANOTIC MELANOMA; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HAMSTER; IMMUNE RESPONSE; INCUBATION TIME; LYMPHOCYTE FUNCTION; MALE; MELANOMA CELL; NATURAL KILLER CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR IMMUNITY; ANIMAL; HUMAN; MELANOMA; METABOLISM; TUMOR CELL CULTURE;

CRICETINAE;

ANIMALS; ANTIGENS, CD95; CRICETINAE; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; MELANOMA; MELANOMA, AMELANOTIC; TUMOR CELLS, CULTURED;

EID: 58949085094     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0041-4     Document Type: Article

References (44)

1. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000; 256:58-66.
2. Nagata S. Early work on the function of CD95, an interview with Shige Nagata. Cell Death Differ. 2004;11(suppl.1):23-27.
3. Bullani RR, Wehrli P, Viard-Leveugle I et al. Frequent down-regulation of Fas (CD95) expression and function in melanoma. Melanoma Res. 2002;12:263-270.
4. Lee H, Ferguson TA. Biology of FasL. Cytokine Growth Factor Rev. 2003;14:325-335.
5. Uckan D, Steele A, Cherry et al. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod. 1997;3:655-662.
6. Griffith TS, Brunner T, Fletcher SM et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
7. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363-1366.
8. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol. 2001;127:20-26.
9. Reimer T, Herrnring C, Koczan D et al. FasL: Fas ratio - a prognostic factor in breast carcinomas. Cancer Res. 2000;60: 822-828.
10. Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57:1007-1012.
11. O'Connell J, O'Sullivan GC, Collins JK et al. The Fas counterattack: Fas mediated T-cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075-1082.
12. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004;23:2950-2966.
13. Martinez-Lorenzo MJ, Anel A, Alava MA et al. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res. 2004;295: 315-329.
14. Böhm I., Schild H. Apoptosis: the complex scenario for silent cell death. Mol Imaging Biol. 2003;5:2-14.
15. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol. 2003;199:275-288.
16. Kroemer G, El-Deiry WS, Goldstein P et al. Classification of cell death: recommendations of the nomenclature committee on cell death. Cell Death Differ. 2005;12:1463-1476.
17. Redondo P, Solano T, Vazquez B et al. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma. Br J Dermatol. 2002;147:80-86.
18. Cichorek M, Kozłowska K, Wachulska M et al. Spontaneous apoptosis of melanotic and amelanotic melanoma cells in different phases of cell cycle: relation to tumor growth. Folia Histochem Cytobiol. 2006;44:31-36.
19. Kozłowska K, Cichorek M, Zarzeczna M et al. Heterogeneous susceptibility to spontaneous and induced apoptosis characterizes two related transplantable melanomas with different biological properties. Pigment Cell Res. 2002;15:233-238.
20. Zielińska K, Kozłowska K, Cichorek M et al. Participation of the Fas/FasL system in spontaneous apoptosis of two transplantable melanoma line cells. Folia Histochem Cytobiol. 2005;43(suppl.1):75-76. Abstracts from IX Conference on Cell Biology, 15-17 September, 2005, Łódź, Poland.
21. Bomirski A, Słomiński A, Bigda J. The natural history of a family of transplantable melanomas in hamsters. Cancer Metastasis Rev. 1988;7:95-118.
22. Bomirski A. A biological properties of transplantable melanomas in the Syrian hamster during 16 years of maintenance by serial passages. Acad Med Ged. 1977.
23. Bomirski A, Dominiczak T, Nowińska L. Spontaneous transplantable melanoma on golden hamster. Acta Union Int Cancer. 1962; 18:178-180.
24. Bomirski A, Kozłowska K, Zurawska-Czupa B. An attempt to prepare nonenzymatically, a single cell suspension from solid transplantable melanomas. Proceedings of the IXth International Conference of Pigment Cell. 1975;5-6, Texas, Houston.
25. Raisova M, Bektas M, Wieder T et al. Resistance to CD95/ Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett. 2000;473:27-32.
26. Gutierrez LS, Noria F, Finol H et al. Fas ligand expression and its correlation with apoptosis and proliferation in Lobund-Wistar prostate carcinomas. Pathobiology. 2005;72: 260-268.
27. Shukuwa T, Katayama I, Koji T. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Mod Pathol. 2002;15:387-396.
28. Soubrane C, Mouawad R, Antoine EC et al. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol. 2000;143:307-312.
29. Tada Y, O-Wang J, Wada A et al. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity. Cancer Gene Ther. 2003;10: 134-140.
30. Cichorek M, Kozłowska K, Bryl E. Mitochondrial transmembrane potential in spontaneous and camptothecin-induced apoptosis of melanotic and amelanotic melanoma cells. Neoplasma. 2007;54:29-36.
31. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med. 2000; 191:1209-1219.
32. Tanaka M, Itai T, Adachi M et al. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31-36.
33. Wada A, Tada Y, Kawamura K et al. The effects of FasL on inflammation and tumor survival are dependent on its expression levels. Cancer Gene Ther. 2007;14:262-267.
34. Kalechman Y, Strassmann G, Albeck M et al. Up-regulation by ammonium trichloro(dioxoethylene-0,0′) tellurate (AS101) of Fas/ Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J Immunol. 1998;161:3536-3542.
35. Terheyden P, Siedel C, Merkel A et al. Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis. J Invest Dermatol. 1999;112:899-902.
36. Peter I, Mezzacasa A, LeDonne P et al. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735, S91-M3. Melanoma Res. 2001;11:21-30.
37. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 1998;282:1714-1717.
38. Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med. 2000;6:493-495.
39. Ryan AE, Lane S, Shanahan F et al. Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. J Carcinog. 2006;5:5.
40. Aggarwal BB, Shishodia S, Sandur SK et al. Inflammation and cancer: how hot is the link?. Biochem Pharmacol. 2006; 72:1605-1621.
41. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004; 14:433-439.
42. Kozłowska K, Zarzeczna M, Cichorek M. Characterization of NO and cytokine release by transplantable melanoma cell lines in relationship to their differentiation. Arch Immunol Ther Exp. 2001;49(suppl.2):103-109.
43. Kozłowska K, Zarzeczna M, Cichorek M et al. Characterization of interleukin 10 and NO release by transplantable melanoma cell lines with regard to their progression. Neoplasma. 2003;50:85-90.
44. Wachulska M, Kozłowska K, Cichorek M. The DNA ploidy and proliferative activity of transplantable melanoma cells in regard to their secretory function. Neoplasma. 2005;52:280-286.